SCHEMBL2640639

SCHEMBL2640639

CC(NC(=O)O)C(=O)Nc1cccc(Cl)c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.55
KMT2A Q03164 7/20 0.55
MAPT P10636 3/20 0.55
LMNA P02545 3/20 0.55
MAPK1 P28482 1/20 0.54
MAPK14 Q16539 4/20 0.50
CXCR2 P25025 1/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
HTT P42858 1/20 0.46
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14519906 0.82 MEN1 (0.61) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL1752734 0.81 MEN1 (0.53) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL16583378 0.80 PTGS2 (0.47) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL1750128 0.80 MEN1 (0.58) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL665304 0.78 MEN1 (0.69) MEN1KMT2AMAPTLMNAMAPK1
Fluoride SCHEMBL11789630 0.77 MEN1 (0.67) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL10710090 0.76 MEN1 (0.79) MEN1KMT2AMAPTLMNAMAPK1
SCHEMBL25342801 0.76 KDM4E (0.56) MEN1KMT2AMAPTLMNANPC1
SCHEMBL25342805 0.76 KDM4E (0.56) MEN1KMT2AMAPTLMNANPC1
SCHEMBL15568569 0.74 MEN1 (0.50) MEN1KMT2AMAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968748-B2 Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest ABIOGEN PHARMA S.P.A. (IT) 2011-06-28 US disclosed
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST ABIOGEN PHARMA S.P.A. (IT) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292129-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST SRR, EPHX2, ALOX5 MEN1 2135/4885KMT2A 4634/4885MAPT 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.